EGFR and non-small cell lung carcinoma: To verify the utility of ctDNA next‐generation sequencing (NGS) in such situations, we planned this prospective study to assess the clinical performance of ctDNA NGS in a multi‐institutional prospective cohort of patients diagnosed with advanced‐stage nonsquamous NSCLC who had been tested for at least EGFR mutations by single‐plex gene analysis and were negative for any driver alterations.